ALNY
Alnylam Pharmaceuticals, Inc.
ALNY offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over ALNY overall, supported by stronger valuation and lower modeled downside.
ALNY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ALNY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ALNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8x | $157 | — |
| Forward | 22x | $157 | — |
| Cheap | 41x | $800 | +411% |
| Fair | 76x | $1,489 | +851% |
| Expensive | 1,731x | $33,895 | +21538% |
Historical ranges are pointers, not guarantees.
ALNY has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ALNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ALNY, but weaker profitability. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ALNY on the outlook, with more favorable valuation and profitability expectations.
ALNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.04 | -64% |
| Q3 2026 | $19.58 | +8413% |
| Q2 2026 | $5.70 | +$8.18 |
| Q1 2026 | $3.98 | +$6.08 |
| Q4 2025 | $2.03 | +$4.21 |
| Q3 2025 | $0.23 | +$2.81 |
| Q2 2025 | -$2.48 | -$1.92 |
| Q1 2025 | -$2.10 | +$0.54 |
| Q4 2024 | -$2.18 | +$1.34 |
ALNY's earnings per share have jumped to their highest in seven years: $19.58 over the past year, up from $0.23 the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ALNY on earnings, with more consistent year-over-year improvement.
ALNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +17% |
| Q2 2026 | $1.3B | +67% |
| Q1 2026 | $1.2B | +96% |
| Q4 2025 | $1.1B | +85% |
| Q3 2025 | $1.2B | +149% |
| Q2 2025 | $773.7M | +17% |
| Q1 2025 | $594.2M | +20% |
| Q4 2024 | $593.2M | +35% |
ALNY has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.7 points |
| Q2 2026 | 18% | +20 points |
| Q1 2026 | 23% | +20 points |
| Q4 2025 | 12% | +30 points |
| Q3 2025 | 29% | +45 points |
| Q2 2025 | -2.1% | -9.5 points |
| Q1 2025 | 3% | +12 points |
| Q4 2024 | -18% | +8.7 points |
ALNY's operating margin was 24% last quarter, down 5.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ALNY on profitability, with a higher operating margin.
ALNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $271.2M | -13% |
| Q2 2026 | $292M | +109% |
| Q1 2026 | $48.7M | +$176M |
| Q4 2025 | $140.3M | +$244M |
| Q3 2025 | $313M | +692% |
| Q2 2025 | $139.4M | +20% |
| Q1 2025 | -$127.3M | -$32.8M |
| Q4 2024 | -$103.8M | -$58.7M |
ALNY has burned cash in most quarters: $752M over the past year, about three times what it generated the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ALNY on cash flow, with more consistent year-over-year improvement.
ALNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -241K shares |
| 1 year | +0.5% | +692K shares |
| 3 years | +5.1% | +6.7M shares |
| 5 years | +16% | +18.9M shares |
| Available history | +24% | +26.3M shares |
ALNY has 138M diluted shares, up 0.5% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ALNY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ALNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -4.6x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
ALNY has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ALNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.6 | Oversold |
| Stochastic | 2.9 | Oversold |
ALNY's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ALNY PE vs Healthcare Sector
| Metric | ALNY | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 26x | 69% below |
| PE % | 2 | 29 | 27 pts below |
ALNY has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ALNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $205.2 | 24% below |
| 20 week MA | $233.7 | 33% below |
| 50 week MA | $293.0 | 47% below |
| 100 week MA | $314.6 | 50% below |
| 200 week MA | $257.7 | 39% below |
ALNY is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ALNY on trend strength, trading above more of its moving averages.
ALNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $117.5 | $137.6 | +17% |
| 2021 | $137.6 | $194.4 | +41% |
| 2022 | $194.4 | $237.9 | +22% |
| 2023 | $237.9 | $191.4 | -20% |
| 2024 | $191.4 | $238.0 | +24% |
| 2025 | $238.0 | $400.6 | +68% |
| 2026 YTD | $400.6 | $156.7 | -61% |
ALNY is down 61% so far in 2026, after finishing higher in five of the previous six years.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ALNY on returns for 2026, with the stronger performance.